These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 23413905)
1. Construction and characterization of a camelized, human, VH-based peptide vaccine against CD20 antigen. Liu J; Tan Y; Zhang R Immunotherapy; 2013 Feb; 5(2):135-41. PubMed ID: 23413905 [TBL] [Abstract][Full Text] [Related]
2. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells. Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465 [TBL] [Abstract][Full Text] [Related]
3. Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. Shan D; Press OW; Tsu TT; Hayden MS; Ledbetter JA J Immunol; 1999 Jun; 162(11):6589-95. PubMed ID: 10352275 [TBL] [Abstract][Full Text] [Related]
4. CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope Spreading. Favoino E; Prete M; Catacchio G; Conteduca G; Perosa F Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003532 [TBL] [Abstract][Full Text] [Related]
5. Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability. Davies J; Riechmann L Protein Eng; 1996 Jun; 9(6):531-7. PubMed ID: 8862554 [TBL] [Abstract][Full Text] [Related]
6. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies. Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806 [TBL] [Abstract][Full Text] [Related]
8. Dependence of the murine antibody response to an anti-CDR2 VH peptide on immunogen formulation. Kanda P; Fritz DA; Gage DA; Shuler KR Mol Immunol; 1995 Dec; 32(17-18):1319-28. PubMed ID: 8643101 [TBL] [Abstract][Full Text] [Related]
9. Fully Human VH Single Domains That Rival the Stability and Cleft Recognition of Camelid Antibodies. Rouet R; Dudgeon K; Christie M; Langley D; Christ D J Biol Chem; 2015 May; 290(19):11905-17. PubMed ID: 25737448 [TBL] [Abstract][Full Text] [Related]
10. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. Haisma HJ; Sernee MF; Hooijberg E; Brakenhoff RH; vd Meulen-Muileman IH; Pinedo HM; Boven E Blood; 1998 Jul; 92(1):184-90. PubMed ID: 9639515 [TBL] [Abstract][Full Text] [Related]
11. [The experimental study on idiotypic DNA vaccine against human B-cell lymphoma to induce antitumor immune response]. Zhong KL; Zhang WJ; Yuan Y; Wu Y; Zhang MW; Mao N Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):609-15. PubMed ID: 14706145 [TBL] [Abstract][Full Text] [Related]
12. Development and Characterization of a New Antipeptide Monoclonal Antibody Directed to Human CD20 Antigen. Habibi-Anbouhi M; Azadmanesh K; Behdani M; Hajizadeh-Saffar E; Vahabpour R; Shokrgozar MA Cancer Biother Radiopharm; 2015 Sep; 30(7):310-6. PubMed ID: 26352927 [TBL] [Abstract][Full Text] [Related]
13. Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells. Hamdy N; Goustin AS; Desaulniers JP; Li M; Chow CS; Al-Katib A J Immunol Methods; 2005 Feb; 297(1-2):109-24. PubMed ID: 15777935 [TBL] [Abstract][Full Text] [Related]
14. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120. Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346 [TBL] [Abstract][Full Text] [Related]
15. Hydrogen deuterium exchange mass spectrometry identifies the dominant paratope in CD20 antigen binding to the NCD1.2 monoclonal antibody. Uhrik L; Hernychova L; Muller P; Kalathiya U; Lisowska MM; Kocikowski M; Parys M; Faktor J; Nekulova M; Nortcliffe C; Zatloukalova P; Ruetgen B; Fahraeus R; Ball KL; Argyle DJ; Vojtesek B; Hupp TR Biochem J; 2021 Jan; 478(1):99-120. PubMed ID: 33284343 [TBL] [Abstract][Full Text] [Related]
16. Peptidomimics of antigen are present in variable region of heavy and light chains of anti-idiotypic antibody and function as surrogate antigen for perpetuation of immunological memory. Vani J; Justin J; Nagasuma RC; Nayak R; Shaila MS Mol Immunol; 2007 Jul; 44(13):3345-54. PubMed ID: 17408744 [TBL] [Abstract][Full Text] [Related]
17. Generation of cytotoxic T lymphocytes specific for B-cell acute lymphoblastic leukemia family-shared peptides derived from immunoglobulin heavy chain framework region. Liu Y; Zhu P; Hu YM Chin Med J (Engl); 2007 Apr; 120(8):652-7. PubMed ID: 17517179 [TBL] [Abstract][Full Text] [Related]
18. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Dakappagari NK; Douglas DB; Triozzi PL; Stevens VC; Kaumaya PT Cancer Res; 2000 Jul; 60(14):3782-9. PubMed ID: 10919651 [TBL] [Abstract][Full Text] [Related]
19. Non-classical binding of a polyreactive α-type anti-idiotypic antibody to B cells. Hernández T; de Acosta CM; López-Requena A; Moreno E; Alonso R; Fernández-Marrero Y; Pérez R Mol Immunol; 2010; 48(1-3):98-108. PubMed ID: 20952071 [TBL] [Abstract][Full Text] [Related]
20. Improved antigen binding by a CD20-specific single-chain antibody fragment with a mutation in CDRH1. Adamson PJ; Millard DJ; Hohmann AW; Mavrangelos C; Macardle PJ; Pilkington G; Mulhern TD; Tedder TF; Zola H; Nicholson IC Mol Immunol; 2006 Feb; 43(6):550-8. PubMed ID: 15936081 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]